Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Gov. Phil Murphy's ideas to cut $100 million from the State Health Benefits Program include charging higher co-pays and ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Eli Lilly (LLY) recently announced promising findings from its SURPASS-CVOT trial, revealing Mounjaro's potential benefits over Trulicity in reducing cardiovascular events. Despite these positive ...

Medical professionals observe that GLP-1 medications like Ozempic show promise for treating rheumatoid arthritis alongside other inflammatory conditions.

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

Discover the evolving trends in plastic surgery as patients, both women and men, opt for smaller, natural-looking results.

A doctor has issued a warning to people who use weight loss jabs over the 'golden dose'. The use of GLP-1 medication, such as ...

GLP-1s are bringing many changes to people's lives. An unexpected and less welcome one? A newfound aversion to meat and other ...

A trial investigating the ability of Eli Lilly’s Mounjaro (tirzepatide) to reduce the risk of cardiovascular issues has met ...